In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells

British Journal of Haematology

Volumn 134, Issue 1, 2006, Pages 37-44

  Neri, Paola ^a,b,c   Yasui, Hiroshi ^a,d   Hideshima, Teru ^a   Tassone, Pierfrancesco ^a,b,c   Raje, Noopur ^a,e   Laurence, Catley P ^a   Ishitsuka, Kenji ^a   Blotta, Simona ^a,b,c   Kiziltepe, Tanyel ^a   Ocio, Enrique M ^a   Fulciniti, Mariateresa ^a,b,c   Kanekal, Sarath ^f   Elliott, Gary T ^f   Munshi, Nikhil C ^a,b   Anderson, Kenneth C ^a,g  

^a HARVARD MEDICAL SCHOOL   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^d SAPPORO MEDICAL UNIVERSITY   (Japan)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f Salmedix Inc   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Dexamethasone; Drug resistance; In vivo mouse model; Multiple myeloma; R etodolac

Indexed keywords

CASPASE; DEXAMETHASONE; ETODOLAC; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME DEGRADATION; EVALUATION; HUMAN; HUMAN CELL; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TUMOR VOLUME; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CASPASES; CELL LINE, TUMOR; DEXAMETHASONE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ETODOLAC; GLUCOCORTICOIDS; HUMANS; I-KAPPA B PROTEINS; IMMUNOBLOTTING; MICE; MICE, SCID; MULTIPLE MYELOMA; POLY(ADP-RIBOSE) POLYMERASES; TRANSPLANTATION, HETEROLOGOUS;

EID: 33744806416     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06122.x     Document Type: Article

References (46)

1. Alexanian R. Dimopoulos M.A. Delasalle K. Barlogie B. 1992 Primary dexamethasone treatment of multiple myeloma. Blood, 80, 887 890.
2. Attal M. Harousseau J.L. Facon T. Guilhot F. Doyen C. Fuzibet J.G. Monconduit M. Hulin C. Caillot D. Bouabdallah R. Voillat L. Sotto J.J. Grosbois B. Bataille R. 2003 Single versus double autologous stem-cell transplantation for multiple myeloma. New England Journal of Medicine, 349, 2495 2502.
3. Auphan N. DiDonato J.A. Rosette C. Helmberg A. Karin M. 1995 Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science, 270, 286 290.
4. Beebe S.J. Holloway R. Rannels S.R. Corbin J.D. 1984 Two classes of cAMP analogs which are selective for the two different cAMP-binding sites of type II protein kinase demonstrate synergism when added together to intact adipocytes. Journal of Biological Chemistry, 259, 3539 3547.
5. Chauhan D. Pandey P. Ogata A. Teoh G. Krett N. Halgren R. Rosen S. Kufe D. Kharbanda S. Anderson K. 1997 Cytochrome c-dependent and -independent induction of apoptosis in multiple myeloma cells. Journal of Biological Chemistry, 272, 29995 29997.
6. Chauhan D. Hideshima T. Pandey P. Treon S. Teoh G. Raje N. Rosen S. Krett N. Husson H. Avraham S. Kharbanda S. Anderson K.C. 1999 RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells. Oncogene, 18, 6733 6740.
7. Chauhan D. Pandey P. Hideshima T. Treon S. Raje N. Davies F.E. Shima Y. Tai Y.T. Rosen S. Avraham S. Kharbanda S. Anderson K.C. 2000 SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. Journal of Biological Chemistry, 275, 27845 27850.
8. Chauhan D. Hideshima T. Rosen S. Reed J.C. Kharbanda S. Anderson K.C. 2001 Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells. Journal of Biological Chemistry, 276, 24453 24456.
9. Chauhan D. Auclair D. Robinson E.K. Hideshima T. Li G. Podar K. Gupta D. Richardson P. Schlossman R.L. Krett N. Chen L.B. Munshi N.C. Anderson K.C. 2002 Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene, 21, 1346 1358.
10. Child J.A. Morgan G.J. Davies F.E. Owen R.G. Bell S.E. Hawkins K. Brown J. Drayson M.T. Selby P.J. 2003 High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New England Journal of Medicine, 348, 1875 1883.
11. Demerson C.A. Humber L.G. Abraham N.A. Schilling G. Martel R.R. Pace-Asciak C. 1983 Resolution of etodolac and antiinflammatory and prostaglandin synthetase inhibiting properties of the enantiomers. Journal of Medicinal Chemistry, 26, 1778 1780.
12. Feinman R. Koury J. Thames M. Barlogie B. Epstein J. Siegel D.S. 1999 Role of NF-κB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood, 93, 3044 3052.
13. Gomi M. Moriwaki K. Katagiri S. Kurata Y. Thompson E.B. 1990 Glucocorticoid effects on myeloma cells in culture: correlation of growth inhibition with induction of glucocorticoid receptor messenger RNA. Cancer Research, 50, 1873 1878.
14. Greenstein S. Krett N.L. Kurosawa Y. Ma C. Chauhan D. Hideshima T. Anderson K.C. Rosen S.T. 2003 Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Experimental Hematology, 31, 271 282.
15. Gregory W.M. Richards M.A. Malpas J.S. 1992 Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. Journal of Clinical Oncology, 10, 334 342.
16. Grogan T.M. Spier C.M. Salmon S.E. Matzner M. Rybski J. Weinstein R.S. Scheper R.J. Dalton W.S. 1993 P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood, 81, 490 495.
17. Hamasaki M. Hideshima T. Tassone P. Neri P. Ishitsuka K. Yasui H. Shiraishi N. Raje N. Kumar S. Picker D.H. Jacob G.S. Richardson P.G. Munshi N.C. Anderson K.C. 2005 Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood, 105, 4470 4476.
18. Hedvat M. Jain A. Carson D.A. Leoni L.M. Huang G. Holden S. Lu D. Corr M. Fox W. Agus D.B. 2004 Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma. Cancer Cell, 5, 565 574.
19. Hideshima T. Anderson K.C. 2002 Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nature Reviews. Cancer, 2, 927 937.
20. Hideshima T. Richardson P. Chauhan D. Palombella V.J. Elliott P.J. Adams J. Anderson K.C. 2001 The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Research, 61, 3071 3076.
21. Hideshima T. Chauhan D. Richardson P. Mitsiades C. Mitsiades N. Hayashi T. Munshi N. Dang L. Castro A. Palombella V. Adams J. Anderson K.C. 2002 NF-κ B as a therapeutic target in multiple myeloma. Journal of Biological Chemistry, 277, 16639 16647.
22. Hideshima T. Mitsiades C. Akiyama M. Hayashi T. Chauhan D. Richardson P. Schlossman R. Podar K. Munshi N.C. Mitsiades N. Anderson K.C. 2003 Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood, 101, 1530 1534.
23. Huls G. Koornstra J.J. Kleibeuker J.H. 2003 Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas. The Lancet, 362, 230 232.
24. Humber L.G. Demerson C.A. Swaminathan P. Bird P.H. 1986 Etodolac (1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid): a potent antiinflammatory drug. Conformation and absolute configuration of its active enantiomer. Journal of Medicinal Chemistry, 29, 871 874.
25. Jenson M. Engert A. Goebeler M.E. Weissinger F. Wilhelm M. Osterborg A. Knauf W. Kimby E.K. Rosen P.J. Poyton C. Rummel M.J. Hillmen P. Oliff I. Kennedy B. Juliusson G. Latven L. Scranton S.A. Paradiso L.J. 2003 A novel pro-apoptotic agent SDX-101 (R-etodolac) for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). Blood, 102, 674a.
26. Karin M. Yamamoto Y. Wang Q.M. 2004 The IKK NF-kappa B system: a treasure trove for drug development. Nature Reviews. Drug Discovery, 3, 17 26.
27. Katagiri S. Yonezawa T. Kuyama J. Kanayama Y. Nishida K. Abe T. Tamaki T. Ohnishi M. Tarui S. 1985 Two distinct human myeloma cell lines originating from one patient with myeloma. International Journal of Cancer, 36, 241 246.
28. Keifer J.A. Guttridge D.C. Ashburner B.P. Baldwin A.S. 2001 Inhibition of NF-kappa B activity by thalidomide through suppression of IκB kinase activity. Journal of Biological Chemistry, 276, 22382 22387.
29. Kolluri S.K. Corr M. James S.Y. Bernasconi M. Lu D. Liu W. Cottam H.B. Leoni L.M. Carson D.A. Zhang X.K. 2005 The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 102, 2525 2530.
30. Kyle R.A. Rajkumar S.V. 2004 Multiple myeloma. New England Journal of Medicine, 351, 1860 1873.
31. Lu D. Zhao Y. Tawatao R. Cottam H.B. Sen M. Leoni L.M. Kipps T.J. Corr M. Carson D.A. 2004 Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 101, 3118 3123.
32. Mitsiades N. Mitsiades C.S. Poulaki V. Chauhan D. Richardson P.G. Hideshima T. Munshi N.C. Treon S.P. Anderson K.C. 2002 Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood, 99, 4525 4530.
33. Mitsiades C.S. Mitsiades N. Munshi N.C. Anderson K.C. 2004 Focus on multiple myeloma. Cancer Cell, 6, 439 444.
34. Ricchi P. Zarrilli R. Di Palma A. Acquaviva A.M. 2003 Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. British Journal of Cancer, 88, 803 807.
35. Richardson P.G. Sonneveld P. Schuster M.W. Irwin D. Stadtmauer E.A. Facon T. Harousseau J.L. Ben-Yehuda D. Lonial S. Goldschmidt H. Reece D. San-Miguel J.F. Blade J. Boccadoro M. Cavenagh J. Dalton W.S. Boral A.L. Esseltine D.L. Porter J.B. Schenkein D. Anderson K.C. 2005 Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352, 2487 2498.
36. Schmidt S. Rainer J. Ploner C. Presul E. Riml S. Kofler R. 2004 Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death and Differentiation, 11 Suppl 1 S45 S55.
37. Tassone P. Neri P. Burger R. Savino R. Shammas M. Catley L. Podar K. Chauhan D. Masciari S. Gozzini A. Tagliaferri P. Venuta S. Munshi N.C. Anderson K.C. 2005 Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clinical Cancer Research, 11, 4251 4258.
38. Tegeder I. Pfeilschifter J. Geisslinger G. 2001 Cyclooxygenase- independent actions of cyclooxygenase inhibitors. FASEB Journal, 15, 2057 2072.
39. Ulrich C.M. Bigler J. Potter J.D. 2006 Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nature Reviews. Cancer, 6, 130 140.
40. Yamamoto Y. Yin M.J. Lin K.M. Gaynor R.B. 1999 Sulindac inhibits activation of the NF-kappaB pathway. Journal of Biological Chemistry, 274, 27307 27314.
41. Yasui H. Adachi M. Imai K. 2003 Combination of tumor necrosis factor-α with sulindac augments its apoptotic potential and suppresses tumor growth of human carcinoma cells in nude mice. Cancer, 97, 1412 1420.
42. Yasui H. Hideshima T. Hamasaki M. Roccaro A.M. Shiraishi N. Kumar S. Tassone P. Ishitsuka K. Raje N. Tai Y.T. Podar K. Chauhan D. Leoni L.M. Kanekal S. Elliott G. Munshi N.C. Anderson K.C. 2005a SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood, 106, 706 712.
43. Yasui H. Hideshima T. Raje N. Roccaro A.M. Shiraishi N. Kumar S. Hamasaki M. Ishitsuka K. Tai Y.T. Podar K. Catley L. Mitsiades C.S. Richardson P.G. Albert R. Brinkmann V. Chauhan D. Anderson K.C. 2005b FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Research, 65, 7478 7484.
44. Yasui H. Hideshima T. Richardson P.G. Anderson K.C. 2006 Novel therapeutic strategies targeting growth factor signaling cascades in multiple myeloma. British Journal of Haematology, 132, 385 397.
45. Yin M.J. Yamamoto Y. Gaynor R.B. 1998 The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature, 396, 77 80.
46. Zhang L. Yu J. Park B.H. Kinzler K.W. Vogelstein B. 2000 Role of BAX in the apoptotic response to anticancer agents. Science, 290, 989 992.